CSF Test Trying to understand like everyone else the likely turn-out of this test. In the companies Nov- PR " Amorfix is currently providing the diagnostic assay technology to a number of Pharmaceutical and Biotech companies on a fee-for- service basis. The data generated by these studies will expand the database and experience wtih the Assay and help to validate its use as a general diagnostic for AD". Key word to me "Validate". In the CEO's letter update nothing new just a re-cap of old stuff, but I liked these words " We are now offering the Assay on a fee-for-service basis and a number of Large Pharmaceutical Corporations are evaluating the test. I liked those words that I hi-lighted and still have the opinion that a Large Pharma will not partner with Amorfix but take them out, especially if the test is the real thing. With billions being spent on a cure for Alzhemier's it would be to valuable for a big company not to scoop it up and have a competitive advantage over its competitors. Left with the thought does just the diagnostic get sold off or the whole thing ?